The Claims and Continuations Final Rule (“Final Rule”) has finally come to an end.

In October 8, 2009, GlaxoSmithKline (“GSK”) has reached agreement with the United States Patent and Trademark Office (“USPTO”) to join the USPTO’s motion to dismiss its litigation over the Final Rule.  The USPTO is withdrawing all Final Rule regulations under dispute.  The withdrawal of the Final Regulations means that the patent system that had been in place before this litigation will remain in place.  The USPTO is revising the rules of practice in this final rule to remove the changes in the Claims and Continuations Final Rule from the Code of Federal Regulations.

[For those readers who are interested in the background of the suit and the definition of the Final Rules (obviously the rules are HISTORY), please click the following link.  Otherwise, you can skip the link and proceed to the next post.]

continue reading “Final Rule.”